Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.
about
Repurposing metformin: an old drug with new tricks in its binding pocketsNew mechanisms of metformin action: Focusing on mitochondria and the gutNeuropharmacological Actions of Metformin in StrokeCellular and molecular mechanisms of metformin: an overviewPPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic DrugsPrenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthoodResveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic controlMetformin stimulates FGF21 expression in primary hepatocytes.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes.Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.Pharmacologic Means of Extending Lifespan.Metformin Ameliorates Dysfunctional Traits of Glibenclamide- and Glucose-Induced Insulin Secretion by Suppression of Imposed Overactivity of the Islet Nitric Oxide Synthase-NO SystemAMPK is involved in the regulation of incretin receptors expression in pancreatic islets under a low glucose concentration.Prenatal metformin exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring.Effects of metformin on energy intake and satiety in obese children.Response to the dipeptidyl peptidase-4 inhibitors in Japanese patients with type 2 diabetes might be associated with a diplotype of two single nucleotide polymorphisms on the interleukin-6 promoter region under a certain level of physical activityEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate CombinationGhrelin: a new incretin enhancer therapy?Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes.The role of incretin therapy at different stages of diabetes.Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.Neuropeptide Y Overexpressing Female and Male Mice Show Divergent Metabolic but Not Gut Microbial Responses to Prenatal Metformin ExposureShort-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.(-)-Epicatechin-3-O-β-D-allopyranoside from Davallia formosana prevents diabetes and dyslipidemia in streptozotocin-induced diabetic mice.Therapy: Metformin takes a new route to clinical efficacy.Exenatide Activates the APPL1-AMPK-PPARα Axis to Prevent Diabetic Cardiomyocyte Apoptosis.Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study.Update on the protective molecular pathways improving pancreatic beta-cell dysfunctionPeroxisome proliferator-activated receptor targets for the treatment of metabolic diseasesEffect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes MellitusComparative anti-inflammatory and lipid-normalizing effects of metformin and omega-3 fatty acids through modulation of transcription factors in diabetic rats.The impact of the metabolic phenotype on thyroid function in obesity.Metformin effects revisited.
P2860
Q22250976-8C905696-C861-4D98-9C2B-DC740186A733Q26778766-457A2982-A8BD-494E-8E21-DB4E1D0DD0BCQ26786307-4513B0AC-74FE-48AC-89D3-B2FA70F2D3A5Q27013561-DBB7CF5A-737B-44AF-AD12-0BC65EF1E0E7Q28066756-0717D21A-69CE-4914-94FB-0BDADD2B0A05Q28486189-C7BE5FF2-E7B7-479C-8D87-6F55F4B1F444Q28743932-1F865448-D61D-432E-8DE2-74FCE82F4FACQ29347106-8F4FCE9A-9813-47DE-A6CE-10C8156F92B3Q30249371-55ABF256-E143-4CD5-B4DA-463D79FAC8EFQ33619167-8B73FD0C-1143-4EEB-8797-692ABA2B47A0Q34265490-E68FF0D1-5114-455E-9FA7-75A140E98221Q34449372-AF979514-7FA8-40AE-9FD4-A0895CE00FFAQ34679569-7B2496FE-7BB0-40A8-9B2E-BA38B916789EQ34746178-1BB4BC0C-65F9-453B-80BD-6B0955C3D73CQ34776628-F6967243-187D-4FAB-97E4-866216A18D2BQ35171164-45778038-D9DA-4A67-A09D-68F5B24C397DQ35192179-38D5BCFA-FF01-451C-9BB1-9A00B537F4D6Q35192184-DB854D6B-EF59-4416-A2B8-D4A977F1A72EQ35532285-995038F1-FFF5-49E1-94CA-9C991CAC829CQ35640531-3B7CFB77-5F6A-429C-B098-FDEBA821410FQ35744498-8AEF68F1-51E7-43D2-BC26-9F7118545AD6Q35760288-8D34EA9A-3079-4FD0-9C79-71DF4474D8E2Q35800392-8B000B67-C64D-4356-9CBD-E7DEF67AF245Q35863219-E48CDA4E-23D7-4A28-BA6A-DC56F05003EFQ36147117-F59266C6-7F33-497F-8973-C745E4ED530DQ36265522-9E4CFB13-ECA8-4D5C-9264-2661485BA7C5Q36319820-93B6549E-9554-4C45-B190-3A063890C755Q36364545-F0C51B4E-5CC2-4EF6-B536-238C88B9F7C8Q36366910-D72FD376-C0AC-4A10-8F3D-107DC93F2827Q36383322-EC71A02A-4BE0-42E9-84F9-9C19DDCC9338Q36508312-12D55F9B-7EFC-44EB-A217-C3DB22A03DD5Q36741706-23F51A2F-FDBE-471E-A8EC-DEAEEEFEF490Q36860811-6207BB39-DC8B-435C-A30C-E8DBB1BE3A61Q36918509-6C6A92D7-BB46-4219-B58E-CDD4CB426FE0Q36990184-3EEF7459-8027-4035-BC9B-BA344C8DFC3DQ37064893-66E65458-3DF2-4EB7-9009-7A37DEB4A463Q37082917-62F86D95-CB63-4F17-821D-6D81C2738E9BQ37142039-21EF9FA3-41D9-4946-A4E4-4ABE0F78F9A2Q37199254-FFBE4622-F5FB-4757-9D84-CA2FAED4AE7EQ37554697-25921978-3F62-4DD8-B06E-7BB8A46455CC
P2860
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Metformin regulates the incret ...... -activated receptor-α in mice.
@en
Metformin regulates the incret ...... -activated receptor-α in mice.
@nl
type
label
Metformin regulates the incret ...... -activated receptor-α in mice.
@en
Metformin regulates the incret ...... -activated receptor-α in mice.
@nl
prefLabel
Metformin regulates the incret ...... -activated receptor-α in mice.
@en
Metformin regulates the incret ...... -activated receptor-α in mice.
@nl
P2093
P2860
P1433
P1476
Metformin regulates the incret ...... -activated receptor-α in mice.
@en
P2093
P2860
P2888
P304
P356
10.1007/S00125-010-1937-Z
P577
2010-10-23T00:00:00Z